Tim Meyer

32.3k total citations · 13 hit papers
237 papers, 13.8k citations indexed

About

Tim Meyer is a scholar working on Oncology, Hepatology and Epidemiology. According to data from OpenAlex, Tim Meyer has authored 237 papers receiving a total of 13.8k indexed citations (citations by other indexed papers that have themselves been cited), including 131 papers in Oncology, 104 papers in Hepatology and 91 papers in Epidemiology. Recurrent topics in Tim Meyer's work include Hepatocellular Carcinoma Treatment and Prognosis (102 papers), Neuroendocrine Tumor Research Advances (55 papers) and Lung Cancer Research Studies (47 papers). Tim Meyer is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (102 papers), Neuroendocrine Tumor Research Advances (55 papers) and Lung Cancer Research Studies (47 papers). Tim Meyer collaborates with scholars based in United Kingdom, United States and Germany. Tim Meyer's co-authors include Andrew K. Burroughs, Gonzalo Sapisochín, Anna Saborowski, Riad Salem, Arndt Vogel, Josep M. Llovet, Gordon Rustin, Tu Vinh Luong, Bruno Sangro and Martyn Caplin and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Tim Meyer

231 papers receiving 13.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hepatocellular carcinoma

2022 1.3k citations Tim Meyer et al. profile →
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

2020 850 citations Masatoshi Kudo, Tim Meyer et al. Journal of Clinical Oncology profile →
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2018 712 citations Arndt Vogel, Tim Meyer et al. profile →
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

2021 633 citations Tim Meyer et al. profile →
Transarterial Therapy for Hepatocellular Carcinoma: Which Technique Is More Effective? A Systematic Review of Cohort and Randomized Studies

2006 617 citations Tim Meyer, Andrew K. Burroughs et al. profile →
A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability

2012 498 citations Tu Vinh Luong, Tim Meyer et al. profile →
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial

2017 331 citations Tim Meyer, Yuk Ting et al. profile →
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines

2021 306 citations Arndt Vogel, Arndt Vogel et al. profile →
Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial

2019 299 citations Tim Meyer, Suzanne L. Topalian et al. Journal of Clinical Oncology profile →
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

2020 240 citations Tim Meyer, Peter R. Galle et al. profile →
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma

2024 145 citations Bruno Sangro, Maxime Ronot et al. Journal of Hepatology profile →
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

2023 136 citations Masatoshi Kudo, Tim Meyer et al. profile →
LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

2022 135 citations Masatoshi Kudo, Philippe Merle et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Tim Meyer	6.7k	4.9k	4.2k	2.6k	2.2k	237	13.8k
Masafumi Ikeda	5.7k 0.9×	6.1k 1.2×	3.0k 0.7×	1.9k 0.7×	1.9k 0.9×	485	12.9k
Sasan Roayaie	6.4k 1.0×	2.7k 0.5×	3.6k 0.9×	3.0k 1.1×	2.8k 1.3×	88	12.0k
Robin Kate Kelley	6.1k 0.9×	6.1k 1.2×	3.0k 0.7×	3.9k 1.5×	3.5k 1.6×	215	15.4k
Mengchao Wu	5.2k 0.8×	3.7k 0.7×	3.3k 0.8×	4.8k 1.9×	3.8k 1.7×	312	13.7k
Michiie Sakamoto	8.0k 1.2×	5.5k 1.1×	5.6k 1.4×	6.5k 2.5×	3.3k 1.5×	406	20.4k
Shigeki Arii	6.5k 1.0×	3.4k 0.7×	3.7k 0.9×	5.4k 2.1×	3.4k 1.5×	307	14.4k
Young Nyun Park	6.8k 1.0×	2.7k 0.6×	5.4k 1.3×	3.7k 1.4×	2.1k 1.0×	391	14.5k
Junji Furuse	3.9k 0.6×	6.6k 1.4×	2.9k 0.7×	2.2k 0.8×	2.2k 1.0×	421	12.7k
Massimo Roncalli	2.7k 0.4×	4.7k 1.0×	2.1k 0.5×	3.2k 1.2×	1.8k 0.8×	228	11.5k
Daniel H. Palmer	3.3k 0.5×	5.3k 1.1×	2.4k 0.6×	2.4k 0.9×	1.9k 0.9×	219	11.7k

Countries citing papers authored by Tim Meyer

Since Specialization

Citations

This map shows the geographic impact of Tim Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Meyer more than expected).

Fields of papers citing papers by Tim Meyer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Meyer. The network helps show where Tim Meyer may publish in the future.

Co-authorship network of co-authors of Tim Meyer

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Meyer. A scholar is included among the top collaborators of Tim Meyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Meyer. Tim Meyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Meisel, Christian, et al.. (2025). Detection of autoantibodies against Interferon Type I in patients with autochthonous West Nile Virus encephalitis. Brain Behavior & Immunity - Health. 48. 101085–101085.

Bhatia, Shailender, Suzanne L. Topalian, William H. Sharfman, et al.. (2025). Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study. Journal of Clinical Oncology. 43(9). 1137–1147. 7 indexed citations

Byrom, Bill, et al.. (2025). Leveraging Patient-Reported Outcome Measures for Optimal Dose Selection in Early Phase Cancer Trials. JMIR Cancer. 11. e64611–e64611. 1 indexed citations

Sangro, Bruno, Maxime Ronot, Valérie Paradis, et al.. (2024). EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. Journal of Hepatology. 82(2). 315–374. 145 indexed citations breakdown →

Wege, Henning, Claudia Campani, Ruben H. de Kleine, et al.. (2024). Rare primary liver cancers: An EASL position paper. Journal of Hepatology. 81(4). 704–725. 4 indexed citations

Vogel, Arndt, Robin Kate Kelley, Philip J. Johnson, et al.. (2023). Predictive and Prognostic Potential of Liver Function Assessment in Patients with Advanced Hepatocellular Carcinoma: A Systematic Literature Review. Liver Cancer. 12(4). 372–391. 6 indexed citations

Meyer, Tim, Mariana Schürmann, Harald Bias, et al.. (2022). Mycobacterium tuberculosis-specific CD4 T-cell scoring discriminates tuberculosis infection from disease. European Respiratory Journal. 60(1). 2101780–2101780. 5 indexed citations

Wong, Yien Ning Sophia, Ayse U. Akarca, Pawan Dhami, et al.. (2022). Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors. Clinical Cancer Research. 28(12). 2657–2668. 7 indexed citations

Rimassa, Lorenza, Robin Kate Kelley, Tim Meyer, et al.. (2021). Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma. Liver Cancer. 11(1). 38–47. 22 indexed citations

10.

Kelley, Robin Kate, Tim Meyer, Lorenza Rimassa, et al.. (2020). Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research. 26(18). 4795–4804. 66 indexed citations

11.

Palmer, Daniel H., Yuk Ting, Markus Peck‐Radosavljevic, et al.. (2018). A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma. British Journal of Cancer. 118(9). 1162–1168. 26 indexed citations

12.

Khan, Mohid S., Amy A. Kirkwood, Theodora Tsigani, et al.. (2015). Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms. Clinical Cancer Research. 22(1). 79–85. 66 indexed citations

13.

Goldstein, Robert M., et al.. (2013). Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer. Expert Review of Anticancer Therapy. 13(3). 359–373. 20 indexed citations

14.

Wu, Jenny, Peter H. Clingen, Victoria J. Spanswick, et al.. (2012). γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000). Clinical Cancer Research. 19(3). 721–730. 50 indexed citations

15.

Khan, Mohid S., Amy A. Kirkwood, Theodora Tsigani, et al.. (2012). Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors. Journal of Clinical Oncology. 31(3). 365–372. 137 indexed citations

16.

Khan, Mohid S., Theodora Tsigani, Mohammed Rashid, et al.. (2011). Circulating Tumor Cells and EpCAM Expression in Neuroendocrine Tumors. Clinical Cancer Research. 17(2). 337–345. 90 indexed citations

17.

Khan, Theodora Tsigani, Jorge García-Hernández, Martyn Caplin, & Tim Meyer. (2011). Circulating Tumor Cells (CTCs) Correlate with Overall Survival in Neuroendocrine Tumors (NETs). UCL Discovery (University College London). 1 indexed citations

18.

Ayaru, Lakshmana, Stephen P. Pereira, Akeel Alisa, et al.. (2007). Unmasking of α-Fetoprotein-Specific CD4+ T Cell Responses in Hepatocellular Carcinoma Patients Undergoing Embolization. The Journal of Immunology. 178(3). 1914–1922. 121 indexed citations

19.

Meyer, Tim, R. Arndt, Enno Christophers, Ingo Nindl, & Eggert Stockfleth. (2001). Importance of human papillomaviruses for the development of skin cancer.. PubMed. 25(6). 533–47. 66 indexed citations

20.

Mitjans, Francesc, Tim Meyer, Claus Fittschen, et al.. (2000). In vivo therapy of malignant melanoma by means of antagonists of αv integrins. International Journal of Cancer. 87(5). 716–723. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact